Core Points - The US District Court for the Southern District of New York ordered Syntel to pay $236.9 million (approximately €204.1 million) to Cognizant/TriZetto as part of the ongoing litigation [1][2][3] - The court awarded pre-judgment interest at a rate of 9% from January 9, 2018, which will be added to the total amount owed [2] - The decision follows a jury's findings from June 30, 2025, which confirmed compensatory damages of $69,977,813 and reduced punitive damages to $139,955,626, contingent on TriZetto's acceptance [6] Company Overview - Atos Group is a global leader in digital transformation with approximately 63,000 employees and annual revenue of around €8 billion, operating in 61 countries [3][4] - The company is recognized as the European leader in cybersecurity, cloud, and high-performance computing, focusing on a secure and decarbonized future [3] - Atos Group operates under two brands: Atos for services and Eviden for products, and is committed to providing AI-powered, end-to-end solutions across various industries [3][4]

Core Insights - Alumis Inc. announced new data from Phase 3 ONWARD1 and ONWARD2 clinical trials for envudeucitinib, a selective oral TYK2 inhibitor for moderate-to-severe plaque psoriasis, presented at the 2026 AAD Annual Meeting [1] Group 1: Clinical Efficacy - Envudeucitinib showed significant skin clearance, with PASI 90 responses at Week 16 being 59.9% and 53.1% for the treatment groups, compared to 4.8% and 4.3% for placebo, increasing to 68.0% and 62.1% at Week 24 [2] - Complete skin clearance (PASI 100) was achieved by 29.4% and 27.7% of envudeucitinib patients at Week 16, rising to 41.0% and 39.5% at Week 24 [2] - Approximately 75% of envudeucitinib patients achieved clear or almost clear scalp psoriasis by Week 24, with over 30% responding as early as Week 4 [3] Group 2: Quality of Life Improvements - Quality-of-life improvements and itch relief were observed before PASI 90 responses, with significant enhancements noted by Week 12, where about 50% of patients achieved DLQI 0/1 [4][7] - Patients experienced an average improvement of over 4 points on the Worst Pruritus Numeric Rating Scale by Week 16, with meaningful itch relief as early as Week 2 [7] Group 3: Safety Profile - Treatment with envudeucitinib was generally well tolerated, with a safety profile consistent with Phase 2 studies, showing no significant laboratory abnormalities or tuberculosis reactivation [5] - Most treatment-emergent adverse events were mild and transient, with common issues including headache, nasopharyngitis, upper respiratory tract infection, and acne [5] Group 4: Future Developments - Alumis plans to submit a New Drug Application to the U.S. FDA in the second half of 2026 and is continuing to evaluate long-term efficacy and safety in the ONWARD3 trial [8] - The ONWARD clinical program involved over 1,700 patients in two parallel trials, assessing the efficacy and safety of envudeucitinib compared to placebo and apremilast [11]

Core Insights - Arcutis Biotherapeutics announced positive results from the INTEGUMENT-INFANT Phase 2 trial for ZORYVE® (roflumilast) cream 0.05%, showing its effectiveness in treating atopic dermatitis in infants aged 3 months to less than 24 months [1][5][6] Group 1: Clinical Trial Results - ZORYVE cream 0.05% significantly reduced signs and symptoms of atopic dermatitis in infants, with caregivers reporting rapid relief of itch in as little as 10 minutes [2][5] - In the trial, 34.4% of participants achieved Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) success at Week 4, and 49% achieved a vIGA-AD score of Clear or Almost Clear [3][4] - The study demonstrated a high safety profile, with only one participant discontinuing due to an adverse event and no serious adverse events reported [2][6] Group 2: Safety and Tolerability - The most frequently reported adverse events included diarrhea, nasopharyngitis, upper respiratory tract infection, and vomiting, with a high local tolerability rate of ≥97.9% experiencing no application site irritation [2][6] - The safety findings were consistent with previous pediatric studies, reinforcing the well-tolerated nature of ZORYVE cream [5][6] Group 3: Future Developments - Arcutis plans to submit a supplemental New Drug Application for ZORYVE cream 0.05% for infants in Q2 2026, expanding its evidence base for this vulnerable population [6] - Additional studies supporting the ZORYVE portfolio were presented, indicating ongoing commitment to developing effective treatments for various dermatological conditions [7][8]

Core Insights - Kymera Therapeutics announced positive results from the BroADen Phase 1b clinical trial of KT-621, an oral STAT6 degrader for atopic dermatitis, presented at the AAD Annual Meeting [1][2] - The trial demonstrated significant reductions in both biomarkers and clinical measures, indicating the potential of KT-621 to improve treatment options for patients with chronic immuno-inflammatory conditions [2][5] Clinical Trial Results - The BroADen Phase 1b trial involved 22 patients with moderate-to-severe atopic dermatitis, showing deep STAT6 degradation with median reductions of 94% in skin and 98% in blood after 28 days of once-daily dosing [2][5] - Significant reductions in Type 2 inflammatory biomarkers were observed, including a median TARC reduction of 74%, Eotaxin-3 reduction of up to 73%, IL-31 reduction of up to 56%, and IgE reduction of up to 14% [2][5] - Clinical activity results included a mean 63% reduction in EASI, 29% EASI-75, 19% vIGA-AD of 0 or 1, 49% reduction in BSA, and 40% reduction in peak pruritus NRS, indicating improvements in skin lesion severity and itch [2][5] Future Development - Kymera is conducting parallel Phase 2b trials for KT-621 in atopic dermatitis (BROADEN2) and asthma (BREADTH), with data expected by mid-2027 and late-2027, respectively [3][5] - These trials aim to accelerate the development of KT-621 for subsequent Phase 3 registration studies across multiple Type 2 inflammatory diseases [3][5] Company Overview - Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases, with a commitment to improving patient outcomes [6] - The company has been recognized as one of Boston's top workplaces and aims to build an industry-leading pipeline of therapies targeting Type 2 inflammatory diseases affecting over 140 million people globally [6][5]

Core Insights - Amlitelimab, a monoclonal antibody targeting OX40-ligand, shows positive results in three phase 3 studies for moderate-to-severe atopic dermatitis, demonstrating significant improvements in skin clearance and disease severity compared to placebo [1][2][3] Study Results - The studies COAST 1, COAST 2, and SHORE were presented at the AAD Annual Meeting, indicating that amlitelimab is well-tolerated and effective as both monotherapy and in combination with topical therapies [1][4] - In COAST 1, 21.1% of patients on Q4W and 22.5% on Q12W achieved a validated investigator global assessment scale score of 0 or 1, compared to 9.2% in the placebo group [5] - COAST 2 showed 25.3% and 25.7% of patients on Q4W and Q12W respectively achieving the same score, against 14.8% in the placebo group [7] - In the SHORE study, 28.7% on Q4W and 32.3% on Q12W achieved the primary endpoint, compared to 16.8% in the placebo group [7] Efficacy and Safety - Amlitelimab demonstrated progressively increasing efficacy over the treatment period with no evidence of plateau at Week 24 [6] - The safety profile was consistent with previous data, with common treatment-emergent adverse events including nasopharyngitis and dermatitis atopic, but overall incidence rates were low [10] - Malignancy rates were low (<1%) across the studies, with no severe injection site reactions reported [10][11] Future Outlook - Results from the ESTUARY phase 3 extension study, evaluating Q12W maintenance dosing and long-term safety, are expected in H2 2026 [12] - Amlitelimab is still in clinical development and has not yet been evaluated by regulatory authorities [12][16]

Core Insights - Vivoryon Therapeutics N.V. presented new data analyses from its varoglutamstat Phase 2 program at the World Congress of Nephrology, highlighting the potential of glutaminyl cyclases as targets in diabetic kidney disease (DKD) [1][2] Group 1: Company Developments - The analyses showed that varoglutamstat can significantly improve kidney function in diabetic patients, with consistent results from two independent Phase 2 studies, VIVIAD and VIVA-MIND [3] - The effect of varoglutamstat on estimated glomerular filtration rate (eGFR) was notably greater in elderly participants with diabetes compared to those without diabetes [3] - In participants with diabetes and lower baseline eGFR (mean 60 mL/min/1.73m), the effect size was comparable or higher than in the overall diabetic population [3] Group 2: Research Findings - Data from a DKD mouse model indicated significant improvements in inflammation, glomerulosclerosis, and kidney function, supporting the validity of targeting glutaminyl cyclases [3] - The results contribute to the growing evidence that inhibiting glutaminyl cyclases can address the underlying inflammatory and fibrotic changes in DKD, reinforcing the development of varoglutamstat for patients with diabetes and advanced chronic kidney disease (CKD) stages [3] Group 3: Presentation Details - The presentation at the World Congress of Nephrology took place on March 28, 2026, at 5:00 pm JST, with the poster titled "Translational Validation of Glutaminyl-Cyclases as Promising New Target for Treatment of DKD" [4] - The presenter was Christine Wenzkowski, PhD, VP of Business Development at Vivoryon [4] Group 4: Company Overview - Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for inflammatory and fibrotic disorders of the kidney, aiming to improve patient outcomes through modulation of pathologically relevant proteins [4] - The company's lead program, varoglutamstat, is a first-in-class orally available QPCT/L inhibitor being evaluated for the treatment of diabetic kidney disease [4]

Financial Performance - As of December 31, 2025, the company had approximately $422.3 million in cash and cash equivalents [6] - Generated revenues of $24.2 million from the sale of 3,970 ounces of gold, with an operating income of $8.7 million, a significant improvement from a loss of $19.8 million in Q4 2024 [6] - Completed a private placement financing for approximately $82.5 million and a prospectus offering for approximately $143.8 million in gross proceeds [5][6] Project Development - The Cariboo Gold Project is advancing with ongoing pre-construction activities, including the construction of critical infrastructure such as a water treatment plant and underground development [5][10] - Released new infill drilling results from the ongoing 13,000-metre underground infill drilling program in the Lowhee Zone, with 11,025 metres completed, representing approximately 80% of the planned program [5][10] - A fully-funded 70,000-metre exploration drilling campaign has been launched to target new discoveries at the Cariboo Gold Project [10] Corporate Updates - The company announced the sale of the San Antonio Gold Project to Axo Copper Corp, which closed on January 27, 2026, resulting in the receipt of common shares and contingent payments [10][21] - Appointed Scott Smith as Vice President of Exploration and Sarah Harrison as Vice President of Permitting & Compliance [10][21] - Included in the VanEck Junior Gold Miners ETF (GDXJ), effective March 20, 2026, which is expected to enhance market visibility and trading liquidity [28] Operational Challenges - Activities at the Cariboo Gold Project were temporarily suspended following a fatal incident on January 22, 2026, but have since resumed under a phased reopening plan [21] - The company is facing challenges in underground development due to difficult ground conditions, which have impacted development rates [10] Future Objectives - The company plans to continue its exploration and infill drilling programs in 2026, with a total of approximately 160,000 metres of planned drilling across all targets [10] - Anticipated costs for various activities in 2026 include $40.2 million for underground development and $6.8 million for regional surface exploration drilling [17]

Core Viewpoint - Miata Metals Corp. has approved the grant of 450,000 stock options to employees and consultants as part of its Omnibus Incentive Equity Plan [1][2] Group 1: Stock Options Details - The stock options will vest 50% at six months and 50% at twelve months, with a three-year term from the grant date and an exercise price of $0.50 per common share [2] - The options and underlying shares are subject to a four-month hold period in accordance with Canadian securities laws and the policies of the Canadian Securities Exchange [2] Group 2: Company Overview - Miata Metals Corp. is a Canadian mineral exploration company listed on the Canadian Securities Exchange, OTCQX, and Frankfurt Exchanges [3] - The company focuses on the acquisition, exploration, and development of mineral properties, holding a 70% interest in the Sela Creek Gold Project and a 70% beneficial interest in the Nassau Gold Project, both located in Suriname's greenstone belt [3]

Core Viewpoint - Constellation Software Inc. announced that Mark Leonard will not seek re-election to the Board of Directors, concluding his term after the annual meeting on May 15, 2026, but will continue as an advisor focusing on the PEMS strategy [1][2]. Group 1 - Mark Leonard, the founder and former President, has been instrumental in building Constellation into a successful global software company with operations in over 150 countries [2][3]. - The PEMS strategy emphasizes selective, long-term minority investments that align with Constellation's acquisition model, and Leonard's expertise will be valuable in this area [2][3]. - The company maintains confidence in its strategy and leadership continuity, highlighting Leonard's foundational influence on its culture and capital allocation [4]. Group 2 - Leonard's motivation for creating a supportive company culture is to enable worthy individuals to succeed, which has been realized in the organization he built [4]. - Constellation Software is publicly traded on the Toronto Stock Exchange under the symbol "CSU" and focuses on acquiring, managing, and building vertical market software businesses [5].

Core Viewpoint - Fusion Fuel Green PLC is set to acquire a 2.0% Net Smelter Return (NSR) royalty on two mineral claims as part of a larger transaction with Royal Uranium Inc, enhancing its portfolio in the uranium sector [1][8]. Company Overview - Fusion Fuel Green PLC is a provider of energy engineering, advisory, and utility solutions, with a focus on integrated energy solutions including green hydrogen [10]. - The company is acquiring a controlling interest in Royal Uranium, which holds a portfolio of 16 royalties across the Americas, aimed at providing exposure to energy commodity royalties [8][11]. Industry Context - The Shea Creek Joint Venture, located in the Western Athabasca Basin, is operated by Orano Canada Inc. and Uranium Energy Corp, benefiting from strong government support and long-term demand driven by France's nuclear energy program [2]. - Global uranium demand is projected to reach 397 million pounds by 2040, a 118% increase from 2025 levels, while supply is expected to grow only 14%, leading to an estimated annual deficit of approximately 197 million pounds [5]. - Development-stage resources in regions like the Western Athabasca Basin are crucial for meeting future uranium demand, especially given the constraints faced by existing producers [6]. Resource Estimates - The Shea Creek Joint Venture has discovered four deposits with significant mineral resource estimates, including 67.57 million pounds indicated and 28.06 million pounds inferred [9]. - UEC's 2022 mineral resource estimate indicates a strong potential for expansion, with extensive drilling completed since 1992 [3][4]. Strategic Acquisition - The acquisition of Royal Uranium is expected to allow Fusion Fuel to benefit from any future discoveries within the claims without incurring additional capital expenditures [7]. - The transaction is part of a strategy to enhance the company's royalty portfolio in uranium and natural gas, providing long-duration exposure to commodity price upside while minimizing operational risks [11].